Venous thromboembolism in patients with Cushing's syndrome: Need of a careful investigation of the prothrombotic risk profile

Pituitary

Volumn 16, Issue 2, 2013, Pages 175-181

  Koutroumpi, S ^a   Daidone, V ^a   Sartori, M T ^a   Cattini, M G ^a   Albiger, N M ^a   Occhi, G ^a   Ferasin, S ^a   Frigo, A ^a   Mantero, F ^a   Casonato, A ^a   Scaroni, C ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

Cushing's syndrome; Prothrombotic risk factors; Venous thromboembolism

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; HYDROCORTISONE; PROTHROMBIN; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BLOOD GROUP ABO SYSTEM; CONTROLLED STUDY; CUSHING SYNDROME; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; FEMALE; GENETIC RISK; GENETIC VARIABILITY; HEMOSTASIS; HIGH RISK PATIENT; HUMAN; HYDROCORTISONE URINE LEVEL; HYPERCORTISOLISM; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROMOTER REGION; RISK ASSESSMENT; RISK FACTOR; UPREGULATION; VENOUS THROMBOEMBOLISM;

ADULT; CUSHING SYNDROME; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 84878769250     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-012-0398-4     Document Type: Article

References (33)

1. Fatti LM, Bottasso B, Invitti C, Coppola R, Cavagnini F, Mannucci PM (2000) Markers of activation of coagulation and fibrinolysis in patients with Cushing's syndrome. J Endocrinol Invest 23:145-150
2. Dal Bo Zanon R, Fornasiero L, Boscaro M, Cappellato G, Fabris F, Girolami A (1982) Increased factor VIII associated activities in Cushing's syndrome: a probable hypercoagulable state. Thromb Haemost 47:116-117
3. Patrassi GM, Dal Bo Zanon R, Boscaro M, Martinelli S, Girolami A (1985) Further studies on the hypercoagulable state of patients with Cushing's syndrome. Thromb Haemost 30:518-520
4. La Brocca A, Terzolo M, Pia A, Paccotti P, De Giuli P, Angeli A (1997) Recurrent thromboembolism as a hallmark of Cushing's syndrome. J Endocrinol Invest 20:211-214
5. Sartori MT, Danesin C, Saggiorato G, Tormene D, Simioni P, Spiezia L, Patrassi GM, Girolami A (2003) The PAI-I gene 4G/5G polymorphism and deep vein thrombosis in patients with inherited thrombophilia. Clin Appl Thromb Hemost 9:299
6. Blann AD (2006) Plasma Von Willebrand factor, thrombosis and the endothelium: the first 30 years; Review. Thromb Haemost 95:49-55
7. Bongers TN, de Maat MP, van Goor ML, Bhagwanbali V, van Vliet HH, Gómez García EB, Dippel DW, Leebeek FW (2006) High Von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation and genetic variability. Stroke 37:2672-2677
8. De Lange M, Snieder H, Ariens R, Spector TD, Grant PJ (2001) The genetics of haemostasis. Lancet 357:101-105
9. Casonato A, Daidone V, Sartorello F, Albiger N, Romualdi C, Mantero F, Pagnan A, Scaroni C (2008) Polymorphisms in von Willebrand factor gene promoter influence the glucocorticoid-induced increase in von Willebrand factor: the lesson learned from Cushing syndrome. Br J Haematol 140:230-235
10. Ageno W, Beccatini C, Brighton T, Selby R, Pieter W (2008) Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 117:93-102
11. Rosendaal FR (2005) Venous thrombosis: the role of genes, environment, and behavior. Hematology American Society of Hematology. Education Program, pp 1-12
12. Casonato A, Pontara E, Boscaro M, Sonino N, Sartorello F, Ferasin S, Girolami A (1999) Abnormalities of Von Willebrand factor are also part of the prothrombotic state of Cushing's syndrome. Blood Coag Fibrinolysis 10:145-151
13. Boscaro M, Sonino N, Scarda A, Barzon L, Fallo F, Sartori MT, Patrassi GM, Girolami A (2002) Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome. J Clin Endocrinol Metab 87:3662-3666
14. Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, Fava GA, Findling JW, Gaillard RC, Grossman AB, Kola B, Lacroix A, Mancini T, Mantero F, Newell-Price J, Nieman LK, Sonino N, Vance ML, Giustina A, Boscaro M (2003) Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 88:5593-5602
15. Casonato A, Pontara E, Sartorello F, Cattini MG, Sartori MT, Padrini R, Girolami A (2002) Reduced von Willebrand factor survival in type vicenza von Willebrand disease. Blood 99:180-184
16. Simioni P, Scudeller A, Radossi P, Gavasso S, Girolami B, Tormene D, Girolami A (1996) Pseudo-homozygous activated protein C resistance due to double heterozygous factor V defect (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds. Thromb Haemost 75:422
17. Simioni P, Tormene D, Manfrin D et al (1998) Prothrombin antigen levels in symptomatic and asymptomatic carriers of the 20210A prothrombin variant. Br J Haematol 103:1045
18. Daidone V, Cattini MG, Pontara E, Sartorello F, Gallinaro L, Marotti A, Scaroni C, Pagnan A, Casonato A (2009) Microsatellite (GT)n repeats and SNPs in the Von Willebrand factor gene promoter do not influence circulating Von Willebrand factor levels under normal conditions. Thromb Haemost 101:298-304
19. Mancini T, Kola B, Mantero F et al (2004) High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol (Oxford) 61:768-777
20. Van Zaane B, Nur E, Squizzato A, Dekkers OM, Twickler MB, Fliers E, Gerdes VEA, Büller HR, Brandjes PM (2009) Hypercoagulable state in Cushing's syndrome: a systematic review. J Clin Endocrinol Metab 94:2743-2750
21. Rees DA, Hanna FW, Davies JS, Mills RG, Vafidis J, Scanlon MF (2002) Long term follow-up results of transsphenoidal surgery for Cushing's disease in a single centre using strict criteria for remission. Clin Endocrinol (Oxford) 56:541-551
22. Manetti L, Bogazzi F, Giovannetti C, Raffaelli V, Genovesi M, Pellegrini G, Ruocco L, Iannelli A, Martino E (2010) Changes of coagulation indexes and occurrence of venous thromboembolism in patients with Cushing's syndrome: results from a retrospective study before and after surgery. Eur J Endocrinol 163:783-791
23. Stuijver DJF, Van Zaane B, Feelders RA et al (2011) Incidence of venous thromboembolism in patients with Cushing's syndrome: a multicenter cohort study. J Clin Endocrinol Metab 96:3525-3532
24. Kastelan D, Dusek T, Kraljevic I, Polasek O, Giljevic Z, Solak M, Zupancic Salek S, Jelcic J, Aganovic I, Korsic M (2009) Hypercoagulability in Cushing's syndrome: the role of the specific haemostatic and fibrinolytic markers. Endocrine 39:70-74
25. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JP, Folsom AR (2002) Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Inter Med 162:1182-1189
26. Heit JA, Leibson CL, Ashrani AA, Petterson TM, Baily RK, Melton LJ (2009) Is diabetes mellitus an independent risk factor for venous thromboembolism? A population-based case-control study. Arterioscler Thromb Vasc Biol 29:1399-1405
27. Pranzy M, Jezkova J. Horova E, Lazarova V, Hana V, Kvasnicka L, Pecen L, Marek J, Skrha J, Ksrek M (2008) Impaired microvascular reactivity and endothelial function in patients with Cushing's syndome: influence of arterial hypertension. Physiol Res 57:13-22
28. Martens I, Considine RV, Van der Planken M, Van Gaal LF (2006) Hemostasis and fibrinolysis in non-diabetic overweight and obese men and women. Is there still a role for leptin? Eur J Endocrinol 155:477-484
29. Ay C, Tengler T, Vormittag R, Simanek R, Dorda W, Vukovich T, Pabinger I (2007) Venous thromboembolism - a manifestation of the metabolic syndrome. Haematologica 92:374-380
30. Rees DC, Cox M, Clegg JB (1995) World distribution of factor V Leiden. Lancet 346:1133-1134
31. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH (1995) High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 85:1504-1508
32. Ceelie H, Spaargaren-van Riel CC, Bertina RM, Vos HL (2004) G20210A is a functional mutation in the prothrombin gene; effect on protein levels and 3′-end formation. J Thrombo Haemost 2:119-127
33. Colucci M, Binetti BM, Tripodi A, Chantarangkul V, Semeraro N (2004) Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated mechanism. Blood 103:2157-2161